Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 6/2023

10-12-2022 | Geriatric Oncology | Review

First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis

Authors: Yu Fujiwara, Hirotaka Miyashita, Bobby C. Liaw

Published in: Cancer Immunology, Immunotherapy | Issue 6/2023

Login to get access

Abstract

Background

Tyrosine kinase inhibitors (TKI) or immune checkpoint blockade (ICB), either alone or in combination, confers a significant overall survival (OS) benefit for metastatic RCC in the first-line setting. However, guidance for optimal treatment selection in elderly patients remains limited.

Methods

A database search was performed to identify eligible randomized controlled trials (RCTs) evaluating first-line regimens for patients with advanced RCC older than 65 years old. The primary outcomes were progression-free survival (PFS) and OS. Indirect comparisons of available regimens were estimated using a random-effects network meta-analysis.

Results

A total of 14 and five RCTs were eligible for PFS and OS analyses. Compared with sunitinib, pembrolizumab plus axitinib (HR 0.68, 95% CI 0.48–0.97) and pembrolizumab plus lenvatinib (HR 0.61, 95% CI 0.4–0.94) were associated with improved OS. Pembrolizumab plus lenvatinib, nivolumab plus cabozantinib, pembrolizumab plus axitinib, and cabozantinib alone each showed improved PFS over sunitinib. Among these, pembrolizumab plus lenvatinib showed better PFS than pembrolizumab plus axitinib (HR 0.58, 95% CI 0.37–0.91), but no PFS difference compared to nivolumab plus cabozantinib (HR 0.63, 95% CI 0.39–1.03) and cabozantinib alone (HR 0.84, 95% CI 0.40–1.77). Network ranking showed pembrolizumab plus lenvatinib provided the favored OS and PFS benefit for elderly patients.

Conclusions

The combination of ICB with TKI such as pembrolizumab plus lenvatinib needs to be considered over monotherapy in the elderly population, but further validation using real-world data or prospective trials is necessary to confirm the efficacy and safety of first-line regimens for the geriatric population with advanced RCC.
Appendix
Available only for authorised users
Literature
1.
Canino C, Perrone L, Bosco E, Saltalamacchia G, Mosca A, Rizzo M et al (2019) Targeting angiogenesis in metastatic renal cell carcinoma. Expert Rev Anticancer Ther 19:245–257PubMedCrossRef
2.
George DJ, Kaelin WG Jr (2003) The von hippel-lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 349:419–421PubMedCrossRef
3.
Powles T (2021) Recent eUpdate to the ESMO Clinical Practice Guidelines on renal cell carcinoma on cabozantinib and nivolumab for first-line clear cell renal cancer: renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 32:422–423PubMedCrossRef
4.
Vuong L, Kotecha RR, Voss MH, Hakimi AA (2019) Tumor microenvironment dynamics in clear-cell renal cell carcinoma. Cancer Discov 9:1349–1357PubMedCrossRef
5.
Yang J, Yan J, Liu B (2018) Targeting VEGF/VEGFR to modulate antitumor immunity. Front Immunol 9:978PubMedCrossRef
6.
Fujiwara Y, Mittra A, Naqash AR, Takebe N (2020) A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy. Cancer Drug Resist 3:252–275PubMed
7.
Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, et al. (2022) Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. Journal of Clinical Oncology. JCO.22.00868.
8.
Massari F, Rizzo A, Mollica V, Rosellini M, Marchetti A, Ardizzoni A et al (2021) Immune-based combinations for the treatment of metastatic renal cell carcinoma: a meta-analysis of randomised clinical trials. Eur J Cancer 154:120–127PubMedCrossRef
9.
Mollica V, Santoni M, Matrana MR, Basso U, De Giorgi U, Rizzo A et al (2022) Concomitant proton pump inhibitors and outcome of patients treated with nivolumab alone or plus ipilimumab for advanced renal cell carcinoma. Target Oncol 17:61–68PubMedCrossRef
10.
Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y et al (2022) Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med 28:704–712PubMedCrossRef
11.
Rizzo A, Mollica V, Santoni M, Massari F (2022) Assessing PD-L1 status in mRCC treated with first-line immune-based combinations: a meta-analysis. Immunotherapy 14:617–625PubMedCrossRef
12.
13.
Landre T, Des Guetz G, Chouahnia K, Fossey-Diaz V, Culine S (2020) Immune checkpoint inhibitors for patients aged ≥ 75 years with advanced cancer in first- and second-line settings: a meta-analysis. Drugs Aging 37:747–754PubMedCrossRef
14.
Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F et al (2021) Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study. JAMA Oncol 7:1856–1861PubMedCrossRef
15.
Kanesvaran R, Le Saux O, Motzer R, Choueiri TK, Scotté F, Bellmunt J et al (2018) Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Lancet Oncol 19:e317–e326PubMedCrossRef
16.
Kaymakcalan MD, Xie W, Albiges L, North SA, Kollmannsberger CK, Smoragiewicz M et al (2016) Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: results from the international metastatic renal cell carcinoma database consortium. Cancer 122:411–419PubMedCrossRef
17.
Varkaris A, Xu W, Davis RB, Healy B, McDermott DF (2020) Combining immune checkpoint and VEGFR inhibition in favorable risk and elderly patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 18:179–84.e3PubMedCrossRef
18.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev 10:89PubMedCrossRef
19.
20.
Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898PubMedCrossRef
21.
Rücker G, Krahn U, König J, Efthimiou O, Davies A, Papakonstantinou T, et al. (2022) Netmeta: network meta-analysis using frequentist methods.
22.
Escudier B, Bellmunt J, Négrier S, Bajetta E, Melichar B, Bracarda S et al (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28:2144–2150PubMedCrossRef
23.
Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103–2111PubMedCrossRef
24.
George DJ, Hessel C, Halabi S, Michaelson MD, Hahn O, Walsh M et al (2019) Cabozantinib versus sunitinib for untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of the alliance A031203 CABOSUN trial. Oncologist 24:1497–1501PubMedPubMedCentralCrossRef
25.
Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK et al (2018) Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma. N Engl J Med 378:1277–1290PubMedPubMedCentralCrossRef
26.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B et al (2021) Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 384:829–841PubMedPubMedCentralCrossRef
27.
Motzer R, Alekseev B, Rha SY, Porta C, Eto M, Powles T et al (2021) Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med 384:1289–1300PubMedCrossRef
28.
Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369:722–731PubMedCrossRef
29.
Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, Hariharan S et al (2014) Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32:752–759PubMedCrossRef
30.
Choueiri TK, Motzer RJ, Rini BI, Haanen J, Campbell MT, Venugopal B et al (2020) Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 31:1030–1039PubMedCrossRef
31.
Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R et al (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol 21:1563–1573PubMedCrossRef
32.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271–2281PubMedCrossRef
33.
Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115–124PubMedCrossRef
34.
Hutson TE, Lesovoy V, Al-Shukri S, Stus VP, Lipatov ON, Bair AH et al (2013) Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14:1287–1294PubMedCrossRef
35.
Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134PubMedCrossRef
36.
Motzer RJ, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipatov O et al (2013) Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol 31:3791–3799PubMedCrossRef
37.
Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRef
38.
World Health O. World report on ageing and health. Geneva: world Health Organization; 2015.
39.
CDC. Indicator Definitions - Older Adults. 2015.
40.
Hermansen CK, Donskov F (2021) Outcomes based on age in patients with metastatic renal cell carcinoma treated with first line targeted therapy or checkpoint immunotherapy: older patients more prone to toxicity. J Geriatr Oncol 12:827–833PubMedCrossRef
41.
Araujo DV, Wells JC, Hansen AR, Dizman N, Pal SK, Beuselinck B et al (2021) Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC)—an international mRCC database consortium (IMDC) analysis. J Geriatr Oncol 12:820–826PubMedCrossRef
42.
Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN et al (2015) Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy. Target Oncol 10:517–522PubMedCrossRef
43.
Daste A, Domblides C, Gross-Goupil M, Chakiba C, Quivy A, Cochin V et al (2017) Immune checkpoint inhibitors and elderly people: a review. Eur J Cancer 82:155–166PubMedCrossRef
44.
Hale P, Hahn AW, Rathi N, Pal SK, Haaland B, Agarwal N (2019) Treatment of metastatic renal cell carcinoma in older patients: a network meta-analysis. J Geriatr Oncol 10:149–154PubMedCrossRef
45.
Massari F, Mollica V, Rizzo A, Cosmai L, Rizzo M, Porta C (2020) Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis. Expert Opin Drug Saf 19:1329–1338PubMedCrossRef
46.
Tomita Y, Motzer RJ, Choueiri TK, Rini BI, Miyake H, Uemura H et al (2022) Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101. ESMO Open 7:100450PubMedPubMedCentralCrossRef
47.
Schulz GB, Rodler S, Szabados B, Graser A, Buchner A, Stief C et al (2020) Safety, efficacy and prognostic impact of immune checkpoint inhibitors in older patients with genitourinary cancers. J Geriatr Oncol 11:1061–1066PubMedCrossRef
48.
Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C et al (2019) Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 393:2404–2415PubMedCrossRef
49.
Rini BI, Stenzl A, Zdrojowy R, Kogan M, Shkolnik M, Oudard S et al (2016) IMA901, a multipeptide cancer vaccine, plus sunitinib versus sunitinib alone, as first-line therapy for advanced or metastatic renal cell carcinoma (IMPRINT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol 17:1599–1611PubMedCrossRef
Metadata
Title
First-line therapy for elderly patients with advanced renal cell carcinoma in the immuno-oncology era: a network meta-analysis
Authors
Yu Fujiwara
Hirotaka Miyashita
Bobby C. Liaw
Publication date
10-12-2022
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 6/2023
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-022-03341-y

Other articles of this Issue 6/2023

Cancer Immunology, Immunotherapy 6/2023 Go to the issue

Research

A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes

Correction

Correction to: Determinants of activity and efficacy of anti-PD1/PD-L1 therapy in patients with advanced solid tumors recruited in a clinical trials unit: a longitudinal prospective biomarker-based study

Research

LINC01004-SPI1 axis-activated SIGLEC9 in tumor-associated macrophages induces radioresistance and the formation of immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma

Research

Real-world experience of postoperative adjuvant chemoimmunotherapy in patients with perihilar cholangiocarcinoma at high risk of recurrence

Original Article

Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma

Research

Endosialin-positive tumor-derived pericytes promote tumor progression through impeding the infiltration of CD8+ T cells in clear cell renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits